1.13
price up icon3.67%   0.04
after-market After Hours: 1.08 -0.05 -4.42%
loading
I Mab Adr stock is traded at $1.13, with a volume of 226.76K. It is up +3.67% in the last 24 hours and down -18.71% over the past month. I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
See More
Previous Close:
$1.09
Open:
$1.07
24h Volume:
226.76K
Relative Volume:
0.63
Market Cap:
$87.66M
Revenue:
$3.91M
Net Income/Loss:
$-206.53M
P/E Ratio:
-0.2969
EPS:
-3.8057
Net Cash Flow:
$-167.78M
1W Performance:
-4.24%
1M Performance:
-18.71%
6M Performance:
-35.80%
1Y Performance:
-38.25%
1-Day Range:
Value
$1.07
$1.14
1-Week Range:
Value
$1.05
$1.2183
52-Week Range:
Value
$0.99
$2.5362

I Mab Adr Stock (IMAB) Company Profile

Name
Name
I Mab Adr
Name
Phone
-
Name
Address
-
Name
Employee
220
Name
Twitter
Name
Next Earnings Date
2024-11-14
Name
Latest SEC Filings
Name
IMAB's Discussions on Twitter

I Mab Adr Stock (IMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-09-21 Initiated Siebert Williams Shank Buy
Jun-02-21 Initiated Daiwa Securities Buy
Mar-15-21 Initiated Needham Buy
Mar-03-21 Reiterated H.C. Wainwright Buy
Feb-25-21 Initiated Piper Sandler Overweight
Dec-07-20 Initiated H.C. Wainwright Buy
Jul-27-20 Initiated Cantor Fitzgerald Overweight
Feb-12-20 Initiated China Renaissance Buy
Feb-11-20 Initiated Jefferies Buy
View All

I Mab Adr Stock (IMAB) Latest News

pulisher
Oct 28, 2024

I-Mab ADR (NASDAQ: IMAB) Stock: Investors Need To Know This - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Would I Buy Spectral AI Inc (NASDAQ: MDAI) Stock At Any Time In The Future? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

If You Don’t Buy Hub Cyber Security Ltd (NASDAQ: HUBC) Now, You’ll Kick Yourself Later - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Itau Unibanco Holding S.A. ADR (NYSE: ITUB) Still Pointing Upwards - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Is Veritone Inc’s (NASDAQ:VERI) Stock On The Decline? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Cisco Systems, Inc. (NASDAQ: CSCO): What’s Next After The Stock Plunge? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Should This Give Tandem Diabetes Care Inc (NASDAQ: TNDM) Investors Sleepless Nights? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Kinross Gold Corp. (NYSE: KGC) Investors Should Be Worried About This. - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Where Do Analysts See Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Heading? - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Not A Good News For Keycorp (NYSE: KEY): The Stock Could Go Down -34.98 Percent More - Stocks Register

Oct 28, 2024
pulisher
Oct 28, 2024

Analyst Forecast For Grab Holdings Limited (NASDAQ: GRAB) - Stocks Register

Oct 28, 2024
pulisher
Oct 24, 2024

Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading - MSN

Oct 24, 2024
pulisher
Oct 09, 2024

IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance

Oct 09, 2024
pulisher
Oct 08, 2024

IMAB’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle

Oct 08, 2024
pulisher
Oct 03, 2024

Company’s Banking Shares: Up -42.43% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle

Oct 03, 2024
pulisher
Sep 26, 2024

It makes sense and dollars to buy I-Mab ADR (IMAB) stock - SETE News

Sep 26, 2024
pulisher
Sep 26, 2024

Ratio Revelations: I-Mab ADR (IMAB)’s Financial Metrics in the Spotlight - The Dwinnex

Sep 26, 2024
pulisher
Sep 25, 2024

I-Mab ADR (IMAB) Stock: From Low to High in 52 Weeks - The InvestChronicle

Sep 25, 2024
pulisher
Sep 25, 2024

IMAB’s price-to-sales ratio: A comparative analysis with its peers - US Post News

Sep 25, 2024
pulisher
Sep 17, 2024

Piper Sandler maintains Overweight rating on I-Mab stock on drug data - Investing.com

Sep 17, 2024
pulisher
Sep 10, 2024

I-Mab reveals Phase 1 data for lung cancer treatment - Investing.com

Sep 10, 2024
pulisher
Sep 05, 2024

Federal Hill Taphouse & Kitchen abruptly closes - WPRI.com

Sep 05, 2024
pulisher
Sep 02, 2024

I-Mab ADR (IMAB)’s stock price in review: A technical analysis - US Post News

Sep 02, 2024
pulisher
Sep 02, 2024

There is no doubt that I-Mab ADR (IMAB) ticks all the boxes. - SETE News

Sep 02, 2024
pulisher
Aug 29, 2024

Earnings call: I-MAB Biopharma discusses pipeline progress and financials - Investing.com India

Aug 29, 2024
pulisher
Aug 28, 2024

I-Mab Reports 1H 2024 Financial Results, Pipeline Progress, and Business Updates - PR Newswire

Aug 28, 2024
pulisher
Jul 16, 2024

Insight venture partners executives sell over $61 million in nCino shares By Investing.com - Investing.com India

Jul 16, 2024
pulisher
Jul 16, 2024

I-Mab appoints new chairman and interim CEO - Investing.com

Jul 16, 2024
pulisher
Jul 15, 2024

2024-07-15 | I-Mab Announces Leadership Transitions | NDAQ:IMAB | Press Release - Stockhouse Publishing

Jul 15, 2024
pulisher
Jul 04, 2024

Financial Health Report: I-Mab ADR (IMAB)'s Ratios Tell a Tale – DWinneX - The Dwinnex

Jul 04, 2024
pulisher
Jun 21, 2024

Teva Acquires Rights to Oncology Biosimilar Candidates - Yahoo News UK

Jun 21, 2024
pulisher
Jun 19, 2024

It is Poised to be a Bull Market for I-Mab ADR (IMAB) – Sete News - SETE News

Jun 19, 2024
pulisher
Jun 06, 2024

I-Mab names new Chief Medical Officer to enhance oncology pipeline - Investing.com India

Jun 06, 2024
pulisher
Jun 06, 2024

I-Mab names new Chief Medical Officer to enhance oncology pipeline By Investing.com - Investing.com

Jun 06, 2024
pulisher
Jun 06, 2024

I-Mab announces clinical trial collaboration with Bristol Myers - TipRanks

Jun 06, 2024
pulisher
Jun 05, 2024

Analysts review I-Mab ADR's rating – Knox Daily - Knox Daily

Jun 05, 2024
pulisher
Jun 05, 2024

I-Mab and Bristol Myers team up for cancer drug trial By Investing.com - Investing.com

Jun 05, 2024
pulisher
Jun 05, 2024

Watch this stock's price performance: I-Mab ADR (NASDAQ:IMAB) – US Post News - US Post News

Jun 05, 2024
pulisher
Jun 05, 2024

I-Mab ADR Inc. (IMAB) Price Performance: A Technical Analysis Perspective - The InvestChronicle

Jun 05, 2024
pulisher
Jun 02, 2024

AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier - Yahoo Lifestyle UK

Jun 02, 2024
pulisher
May 27, 2024

Check out these key findings about I-Mab ADR (IMAB) – Sete News - SETE News

May 27, 2024
pulisher
May 23, 2024

I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024 - GlobeNewswire Inc.

May 23, 2024
pulisher
May 19, 2024

AbbVie Partners With Chinese Biotech for Cancer Candidate - Yahoo News NZ

May 19, 2024
pulisher
May 07, 2024

(IMAB)Analyzing I-MAB's Short Interest By Benzinga - Investing.com UK

May 07, 2024
pulisher
May 02, 2024

Here's Why IMab Sponsored ADR (IMAB) is Poised for a Turnaround After Losing 26.8% in 4 Weeks - Yahoo Lifestyle UK

May 02, 2024
pulisher
May 01, 2024

Patent Law Changes Pose Threat to I-Mab Adr's Drug Candidate ProtectionTipRanks.com - TipRanks

May 01, 2024
pulisher
Apr 15, 2024

I-Mab Announces CMO Transition, Interim Successor NamedTipRanks.com - TipRanks

Apr 15, 2024
pulisher
Apr 02, 2024

I-Mab Finalizes Divestiture and Resolves ObligationsTipRanks.com - TipRanks

Apr 02, 2024
pulisher
Mar 18, 2024

Piper Sandler cuts I-Mab stock target to $10, keeps overweight rating - Investing.com

Mar 18, 2024
pulisher
Mar 12, 2024

symbol__ Stock Quote Price and Forecast - CNN

Mar 12, 2024
pulisher
Sep 09, 2023

Minnelide combined with anti-ANGPTL3-FLD monoclonal antibody completely protects mice with adriamycin nephropathy by promoting autophagy and inhibiting apoptosis - Nature.com

Sep 09, 2023

I Mab Adr Stock (IMAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):